These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

290 related articles for article (PubMed ID: 27903463)

  • 1. HER2 Transmembrane Domain (TMD) Mutations (V659/G660) That Stabilize Homo- and Heterodimerization Are Rare Oncogenic Drivers in Lung Adenocarcinoma That Respond to Afatinib.
    Ou SI; Schrock AB; Bocharov EV; Klempner SJ; Haddad CK; Steinecker G; Johnson M; Gitlitz BJ; Chung J; Campregher PV; Ross JS; Stephens PJ; Miller VA; Suh JH; Ali SM; Velcheti V
    J Thorac Oncol; 2017 Mar; 12(3):446-457. PubMed ID: 27903463
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical and molecular characteristics of Chinese non-small cell lung cancer patients with ERBB2 transmembrane domain mutations.
    Fan Y; Qiu J; Yu R; Cao R; Chen X; Ou Q; Wu X; Shao YW; Nagasaka M; Zhang J; Ou SI
    Mol Oncol; 2020 Aug; 14(8):1731-1739. PubMed ID: 32478891
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Therapeutic Potential of Afatinib for Cancers with
    Yamamoto H; Toyooka S; Ninomiya T; Matsumoto S; Kanai M; Tomida S; Kiura K; Muto M; Suzawa K; Desmeules P; Kris MG; Li BT; Ladanyi M
    Oncologist; 2018 Feb; 23(2):150-154. PubMed ID: 29146616
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical Activity of Pan-HER Inhibitors Against HER2-Mutant Lung Adenocarcinoma.
    Oh IJ; Hur JY; Park CK; Kim YC; Kim SJ; Lee MK; Kim HJ; Lee KY; Lee JC; Choi CM
    Clin Lung Cancer; 2018 Sep; 19(5):e775-e781. PubMed ID: 30149884
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Antitumor effect of afatinib, as a human epidermal growth factor receptor 2-targeted therapy, in lung cancers harboring HER2 oncogene alterations.
    Suzawa K; Toyooka S; Sakaguchi M; Morita M; Yamamoto H; Tomida S; Ohtsuka T; Watanabe M; Hashida S; Maki Y; Soh J; Asano H; Tsukuda K; Miyoshi S
    Cancer Sci; 2016 Jan; 107(1):45-52. PubMed ID: 26545934
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pulse Afatinib for ERBB2 Exon 20 Insertion-Mutated Lung Adenocarcinomas.
    Costa DB; Jorge SE; Moran JP; Freed JA; Zerillo JA; Huberman MS; Kobayashi SS
    J Thorac Oncol; 2016 Jun; 11(6):918-23. PubMed ID: 26964772
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy of Afatinib in a Previously-Treated Patient with Non-Small Cell Lung Cancer Harboring HER2 Mutation: Case Report.
    Park CK; Hur JY; Choi CM; Kim TO; Cho HJ; Shin HJ; Lim JH; Choi YD; Kim YC; Oh IJ
    J Korean Med Sci; 2018 Jan; 33(1):e7. PubMed ID: 29215816
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Afatinib in NSCLC With HER2 Mutations: Results of the Prospective, Open-Label Phase II NICHE Trial of European Thoracic Oncology Platform (ETOP).
    Dziadziuszko R; Smit EF; Dafni U; Wolf J; Wasąg B; Biernat W; Finn SP; Kammler R; Tsourti Z; Rabaglio M; Ruepp B; Roschitzki-Voser H; Stahel RA; Felip E; Peters S
    J Thorac Oncol; 2019 Jun; 14(6):1086-1094. PubMed ID: 30825613
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Lung cancer that harbors an HER2 mutation: epidemiologic characteristics and therapeutic perspectives.
    Mazières J; Peters S; Lepage B; Cortot AB; Barlesi F; Beau-Faller M; Besse B; Blons H; Mansuet-Lupo A; Urban T; Moro-Sibilot D; Dansin E; Chouaid C; Wislez M; Diebold J; Felip E; Rouquette I; Milia JD; Gautschi O
    J Clin Oncol; 2013 Jun; 31(16):1997-2003. PubMed ID: 23610105
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical activity of afatinib (BIBW 2992) in patients with lung adenocarcinoma with mutations in the kinase domain of HER2/neu.
    De Grève J; Teugels E; Geers C; Decoster L; Galdermans D; De Mey J; Everaert H; Umelo I; In't Veld P; Schallier D
    Lung Cancer; 2012 Apr; 76(1):123-7. PubMed ID: 22325357
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Targeting HER2 aberrations as actionable drivers in lung cancers: phase II trial of the pan-HER tyrosine kinase inhibitor dacomitinib in patients with HER2-mutant or amplified tumors.
    Kris MG; Camidge DR; Giaccone G; Hida T; Li BT; O'Connell J; Taylor I; Zhang H; Arcila ME; Goldberg Z; Jänne PA
    Ann Oncol; 2015 Jul; 26(7):1421-7. PubMed ID: 25899785
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Lung cancer patients with HER2 mutations treated with chemotherapy and HER2-targeted drugs: results from the European EUHER2 cohort.
    Mazières J; Barlesi F; Filleron T; Besse B; Monnet I; Beau-Faller M; Peters S; Dansin E; Früh M; Pless M; Rosell R; Wislez M; Fournel P; Westeel V; Cappuzzo F; Cortot A; Moro-Sibilot D; Milia J; Gautschi O
    Ann Oncol; 2016 Feb; 27(2):281-6. PubMed ID: 26598547
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Actionable Activating Oncogenic ERBB2/HER2 Transmembrane and Juxtamembrane Domain Mutations.
    Pahuja KB; Nguyen TT; Jaiswal BS; Prabhash K; Thaker TM; Senger K; Chaudhuri S; Kljavin NM; Antony A; Phalke S; Kumar P; Mravic M; Stawiski EW; Vargas D; Durinck S; Gupta R; Khanna-Gupta A; Trabucco SE; Sokol ES; Hartmaier RJ; Singh A; Chougule A; Trivedi V; Dutt A; Patil V; Joshi A; Noronha V; Ziai J; Banavali SD; Ramprasad V; DeGrado WF; Bueno R; Jura N; Seshagiri S
    Cancer Cell; 2018 Nov; 34(5):792-806.e5. PubMed ID: 30449325
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Afatinib combined with anlotinib in the treatment of lung adenocarcinoma patient with novel HER2 mutation: a case report and review of the literature.
    Xu H; Liang Q; Xu X; Tan S; Wang S; Liu Y; Liu L
    World J Surg Oncol; 2021 Nov; 19(1):330. PubMed ID: 34794435
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Novel germline mutation in the transmembrane domain of HER2 in familial lung adenocarcinomas.
    Yamamoto H; Higasa K; Sakaguchi M; Shien K; Soh J; Ichimura K; Furukawa M; Hashida S; Tsukuda K; Takigawa N; Matsuo K; Kiura K; Miyoshi S; Matsuda F; Toyooka S
    J Natl Cancer Inst; 2014 Jan; 106(1):djt338. PubMed ID: 24317180
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comprehensive investigation of oncogenic driver mutations in Chinese non-small cell lung cancer patients.
    Wang R; Zhang Y; Pan Y; Li Y; Hu H; Cai D; Li H; Ye T; Luo X; Zhang Y; Li B; Shen L; Sun Y; Chen H
    Oncotarget; 2015 Oct; 6(33):34300-8. PubMed ID: 26486077
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Poziotinib in Non-Small-Cell Lung Cancer Harboring
    Le X; Cornelissen R; Garassino M; Clarke JM; Tchekmedyian N; Goldman JW; Leu SY; Bhat G; Lebel F; Heymach JV; Socinski MA
    J Clin Oncol; 2022 Mar; 40(7):710-718. PubMed ID: 34843401
    [TBL] [Abstract][Full Text] [Related]  

  • 18. ERBB2-Mutated Metastatic Non-Small Cell Lung Cancer: Response and Resistance to Targeted Therapies.
    Chuang JC; Stehr H; Liang Y; Das M; Huang J; Diehn M; Wakelee HA; Neal JW
    J Thorac Oncol; 2017 May; 12(5):833-842. PubMed ID: 28167203
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The presence of HER2 exon 20 insertion in patients with central nervous system metastases from non-small lung cancer--a potential application in classification for therapy.
    Nicoś M; Krawczyk P; Mlak R; Sawicki M; Jarosz B; Powrózek T; Milanowski P; Trojanowski T; Milanowski J
    Pneumonol Alergol Pol; 2013; 81(4):294-7. PubMed ID: 23744164
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Identification of Recurrent Activating
    Lorch G; Sivaprakasam K; Zismann V; Perdigones N; Contente-Cuomo T; Nazareno A; Facista S; Wong S; Drenner K; Liang WS; Amann JM; Sinicropi-Yao SL; Koenig MJ; La Perle K; Whitsett TG; Murtaza M; Trent JM; Carbone DP; Hendricks WPD
    Clin Cancer Res; 2019 Oct; 25(19):5866-5877. PubMed ID: 31431454
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.